Regencell Bioscience Lim... (RGC)
4.86
0.05 (1.04%)
At close: Jan 14, 2025, 3:28 PM
4.86
0.00%
After-hours Jan 14, 2025, 03:28 PM EST
Company Description
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.
It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Limited
| Country | HK |
| IPO Date | Jul 16, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Yat-Gai Au |
Contact Details
Address: First Commercial Building Causeway Bay, HK | |
| Website | https://www.regencellbioscience.com |
Stock Details
| Ticker Symbol | RGC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001829667 |
| CUSIP Number | G7487R100 |
| ISIN Number | KYG7487R1002 |
| Employer ID | 00-0000000 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Yat-Gai Au | Founder, Chairman & Chief Executive Officer |
| Wai Hong Chung | Chief Operating Officer, Chief Strategy Officer & Director |
| Antonia Assang | Senior Vice President of Project Management |
| Michelle Chan | Financial Controller & Principal Financial Officer |
| Yat-Pui Au | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 25, 2024 | 20-F | Filing |
| Jun 20, 2024 | 6-K | Filing |
| Jan 02, 2024 | 6-K | Filing |
| Dec 15, 2023 | 6-K | Filing |
| Oct 27, 2023 | 20-F | Filing |
| Jun 15, 2023 | 6-K | Filing |
| Jun 05, 2023 | 6-K | Filing |
| Mar 17, 2023 | 6-K | Filing |
| Feb 28, 2023 | 6-K | Filing |
| Jan 04, 2023 | 6-K | Filing |